Characterizing the development of the most relevant species, putatively AβOs, and their association with other pathological changes in AD, such as glial activation or phosphorylated tau (pTau) accumulation, is necessary to better understand disease progression in this model. This evidence concerns the gene MAPT and Alzheimer disease.